A systematic review of biomarkers for disease progression in Alzheimer's disease.

<h4>Background</h4>Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process. A systematic review was undertaken to d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David J M McGhee, Craig W Ritchie, Paul A Thompson, David E Wright, John P Zajicek, Carl E Counsell
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ff5c14770f064f16b884a63baec52225
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff5c14770f064f16b884a63baec52225
record_format	dspace
spelling	oai:doaj.org-article:ff5c14770f064f16b884a63baec522252021-11-18T08:32:14ZA systematic review of biomarkers for disease progression in Alzheimer's disease.1932-620310.1371/journal.pone.0088854https://doaj.org/article/ff5c14770f064f16b884a63baec522252014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24558437/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process. A systematic review was undertaken to determine what biomarkers for disease progression in Alzheimer's disease exist and how well they perform.<h4>Methods</h4>MEDLINE and Embase (1950-2011) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with probable Alzheimer's disease diagnosed by formal criteria were included. We made no restriction on age, disease duration, or drug treatment. We only included studies with a longitudinal design, in which the putative biomarker and clinical measure were both measured at least twice, as this is the only appropriate study design to use when developing a disease progression biomarker. We included studies which attempted to draw associations between the changes over time in the biomarker used to investigate disease progression and a clinical measure of disease progression.<h4>Results</h4>Fifty-nine studies were finally included. The commonest biomarker modality examined was brain MRI (17/59, 29% of included studies). Median follow-up in included studies was only 1.0 (IQR 0.8-1.7) year and most studies only measured the putative biomarker and clinical measure twice. Included studies were generally of poor quality with small numbers of participants (median 31 (IQR 17 to 64)), applied excessively restrictive study entry criteria, had flawed methodologies and conducted overly simplistic statistical analyses without adjusting for confounding factors.<h4>Conclusions</h4>We found insufficient evidence to recommend the use of any biomarker as an outcome measure for disease progression in Alzheimer's disease trials. However, further investigation into the efficacy of using MRI measurements of ventricular volume and whole brain volume appeared to be merited. A provisional 'roadmap' to improve the quality of future disease progression biomarker studies is presented.David J M McGheeCraig W RitchiePaul A ThompsonDavid E WrightJohn P ZajicekCarl E CounsellPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e88854 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q David J M McGhee Craig W Ritchie Paul A Thompson David E Wright John P Zajicek Carl E Counsell A systematic review of biomarkers for disease progression in Alzheimer's disease.
description	<h4>Background</h4>Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true slowing of the neurodegenerative process. A systematic review was undertaken to determine what biomarkers for disease progression in Alzheimer's disease exist and how well they perform.<h4>Methods</h4>MEDLINE and Embase (1950-2011) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with probable Alzheimer's disease diagnosed by formal criteria were included. We made no restriction on age, disease duration, or drug treatment. We only included studies with a longitudinal design, in which the putative biomarker and clinical measure were both measured at least twice, as this is the only appropriate study design to use when developing a disease progression biomarker. We included studies which attempted to draw associations between the changes over time in the biomarker used to investigate disease progression and a clinical measure of disease progression.<h4>Results</h4>Fifty-nine studies were finally included. The commonest biomarker modality examined was brain MRI (17/59, 29% of included studies). Median follow-up in included studies was only 1.0 (IQR 0.8-1.7) year and most studies only measured the putative biomarker and clinical measure twice. Included studies were generally of poor quality with small numbers of participants (median 31 (IQR 17 to 64)), applied excessively restrictive study entry criteria, had flawed methodologies and conducted overly simplistic statistical analyses without adjusting for confounding factors.<h4>Conclusions</h4>We found insufficient evidence to recommend the use of any biomarker as an outcome measure for disease progression in Alzheimer's disease trials. However, further investigation into the efficacy of using MRI measurements of ventricular volume and whole brain volume appeared to be merited. A provisional 'roadmap' to improve the quality of future disease progression biomarker studies is presented.
format	article
author	David J M McGhee Craig W Ritchie Paul A Thompson David E Wright John P Zajicek Carl E Counsell
author_facet	David J M McGhee Craig W Ritchie Paul A Thompson David E Wright John P Zajicek Carl E Counsell
author_sort	David J M McGhee
title	A systematic review of biomarkers for disease progression in Alzheimer's disease.
title_short	A systematic review of biomarkers for disease progression in Alzheimer's disease.
title_full	A systematic review of biomarkers for disease progression in Alzheimer's disease.
title_fullStr	A systematic review of biomarkers for disease progression in Alzheimer's disease.
title_full_unstemmed	A systematic review of biomarkers for disease progression in Alzheimer's disease.
title_sort	systematic review of biomarkers for disease progression in alzheimer's disease.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/ff5c14770f064f16b884a63baec52225
work_keys_str_mv	AT davidjmmcghee asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT craigwritchie asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT paulathompson asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT davidewright asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT johnpzajicek asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT carlecounsell asystematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT davidjmmcghee systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT craigwritchie systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT paulathompson systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT davidewright systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT johnpzajicek systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease AT carlecounsell systematicreviewofbiomarkersfordiseaseprogressioninalzheimersdisease
_version_	1718421720973443072

A systematic review of biomarkers for disease progression in Alzheimer's disease.

Ejemplares similares